fosbretabulin tromethamine + bevacizumab + physician's choice chemotherapy

This is a **combination regimen** consisting of three main components: **fosbretabulin tromethamine** (a vascular disrupting agent and prodrug of combretastatin A-4 phosphate, which destabilizes microtubules and disrupts tumor vasculature), **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A, inhibiting angiogenesis), and **physician's choice chemotherapy** (which refers to guideline-driven standard chemotherapy selected by the treating physician, commonly platinum-based agents or other standard-of-care choices for the cancer in question). This multi-agent regimen is used in investigational settings for advanced, refractory, or aggressive cancers such as anaplastic thyroid cancer and certain solid tumors. - **Fosbretabulin tromethamine** is a small molecule prodrug; it is converted in vivo to combretastatin A4, which inhibits tubulin polymerization, causing apoptosis of endothelial cells in tumor vasculature, and results in blockade of blood supply and tumor necrosis[1][3][7][9]. - **Bevacizumab** is a humanized monoclonal antibody that binds VEGF-A, thereby inhibiting new blood vessel formation and reducing tumor growth and metastatic spread[2][4][6][8]. - **Physician's choice chemotherapy** refers to the inclusion of a standard chemotherapy agent based on best clinical judgement and protocols for the specific cancer being treated.

Brand names

Zybrestat (for fosbretabulin tromethamine)Avastin (for bevacizumab)

Other names

fosbretabulin tromethaminefosbretabulin disodiumcombretastatin A-4 phosphateCA4PDCA-4PDCA 4PD2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (for fosbretabulin tromethamine)CA4P (common code name)bevacizumabphysician's choice chemotherapy